ERBB2 and breast cancer: In sensitivity analyses that included breast cancer with HER2-positive, borderline, or unknown status in 2010–2015 dataset (n = 1152, 5.5% of total breast cancer cases), similar results were found: patients with the RS 26–30 had poor survival than those with the RS 18–25 (Fig. 2).